Therapy News and Research

RSS

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

Cefpodoxime not effective in treating uncomplicated cystitis in women

Short-term use of the antibiotic cefpodoxime for the treatment of women with uncomplicated cystitis (bladder infection) did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin, a drug in the fluoroquinolone class of antibiotics for which there have been concerns about overuse and a resulting increase in resistance rates, according to a study in the February 8 issue of JAMA.

8 Feb 2012

New immunotherapy combination prolongs survival in dogs with NHL

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports.

8 Feb 2012

New smartphone can help people with mental health problems

Brooding in your apartment on Saturday afternoon? A new smart phone intuits when you're depressed and will nudge you to call or go out with friends. It's the future of therapy at a new Northwestern University Feinberg School of Medicine center where scientists are inventing web-based, mobile and virtual technologies to treat depression and other mood disorders. The phone and similar projects bypass traditional weekly therapy sessions for novel approaches that provide immediate support and access to a much larger population.

8 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Tailoring TB treatment based on a patient's genetic sequence

A gene that influences the inflammatory response to infection may also predict the effectiveness of drug treatment for a deadly form of tuberculosis.

8 Feb 2012

Forum for Collaborative HIV Research suggests new approach for conducting Phase 3 HIV clinical trials

As the war on HIV/AIDS begins its fourth decade, medical researchers, pharmaceutical manufacturers, patient advocates and government regulators face a new and unexpected scientific challenge: how to demonstrate the safety and efficacy of promising new antiretroviral drugs when the two traditional study designs – the superiority trial and the non-inferiority trial – are no longer useful in showing improvements in both "treatment experienced" patients and those who have never received drug therapy (treatment-naive patients).

7 Feb 2012

FDA reviews Amgen’s prostate cancer drug Xgeva

U.S. Food and Drug Administration (FDA) researchers say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.

7 Feb 2012

Antiretroviral therapy does not increase severity of psychiatric disorders

A study of more than 300 children and adolescents with human immunodeficiency virus (HIV) revealed no association between specific antiretroviral therapy and the severity of psychiatric disorders.

7 Feb 2012

Proactive test-and-treat case-detection strategy can combat malaria

As researchers work to eliminate malaria worldwide, new strategies are needed to find and treat individuals who have malaria, but show no signs of the disease. The prevalence of asymptomatic or minimally symptomatic malaria can be as high as 35 percent in populations with malaria and these asymptomatic individuals can serve as a reservoir for spreading malaria even in areas where disease transmission has declined.

7 Feb 2012

TGen to host Pediatric Cancer Translational Genomics in Scottsdale

The Translational Genomics Research Institute (TGen) will host Pediatric Cancer Translational Genomics Feb. 6-8 at the Hotel Valley Ho in Scottsdale, bringing together more than 150 leading pediatric cancer researchers, clinicians and foundations to promote the exchange of information and ideas for advancing pediatric cancer research and treatment.

7 Feb 2012

Cyclin D1 oncogene may promote chromosomal instability

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

7 Feb 2012

Novel stem-cell technique to enhance bone growth

A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones.

7 Feb 2012

New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.

7 Feb 2012

Book focuses on Group Schema Therapy for BPD

Therapists, patients and families dealing with Borderline Personality Disorder now have an unprecedented guide to a way out of the misery and chaos in the form of the soon to be release book "Group Schema Therapy for Borderline Personality Disorder: Treatment Manual and Patient Workbook".

7 Feb 2012

Epilepsy surgery improves QOL and long-term seizure control

While epilepsy surgery is a safe and effective intervention for seizure control, medical therapy remains the more prominent treatment option for those with epilepsy. However, a new 26-year study reveals that following epilepsy surgery, nearly half of participants were free of disabling seizures and 80% reported better quality of life than before surgery.

7 Feb 2012

BPS Annual Meeting to be held Feb. 25 - 29 in San Diego

The latest news and discoveries in medicine, physics, environmental science, and interdisciplinary fields will be featured at the 56th Annual Meeting of the Biophysical Society (BPS), held Feb. 25 - Feb. 29, 2012, at the San Diego Convention Center in San Diego, Calif. With more than 4,000 poster presentations, 200 exhibits, 20 symposia, and 6,000 research scientists in attendance each year, the BPS Annual Meeting is the largest meeting of biophysicists in the world.

7 Feb 2012

Low-dose MNC hUCB therapy effective in ALS-modeled mice

Repeated, low-dose injections of mononuclear cells derived from human umbilical cord blood have been found effective in protecting motor neuron cells, delaying disease progression and increasing lifespan for mice modeling amyotrophic lateral sclerosis, or ALS, also referred to as Lou Gehrig's disease, report University of South Florida researchers and colleagues from Saneron CCEL Therapeutics, Inc., and the Ribeirao Preto School of Medicine at the University of Sao Paulo, Brazil.

7 Feb 2012

Researchers reveal how molecular imaging can solve breast cancer mysteries

In two new studies featured in the February issue of the Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult cases of breast cancer.

7 Feb 2012

New ACCP guidelines address DVT/PE risk factors for long-distance travel

New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.

7 Feb 2012